Clinical trials: Anticoagulant
Arterial Occlusion, Angina Pectoris
Comparing TR Band to Statseal in Conjunction With TR Band
The primary objectives of this study are to evaluate the performance of StatSeal Advanced used in conjunction with the TR Band (SSA) as compared to the TR Band without SSA (TRB) relative to: the incidence of peri-procedural…
- Conditions
- Arterial Occlusion, Angina Pectoris, Cardiovascular Diseases, Atherosclerosis
- Trial name
- NCT03028025
- Testing
- StatSeal, TR Band
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- VA Long Beach Healthcare System
Cancer, Rivaroxaban
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.
- Conditions
- Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis
- Trial name
- VALERIA (NCT04999176)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- Brazil
- Volunteers
- 440 people
- Sponsor
- André Luiz Malavasi Longo de Oliveira
Coronary Artery Disease, Ischemic Heart Disease
The Randomized OPTIMAL-ACT Trial
The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Anticoagulant-induced Bleeding, Coronary Syndrome
- Trial name
- NCT03772613
- Testing
- Unfractionated heparin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Mayo Clinic
Blood Coagulation
Safety of Oral Anticoagulants Registry
The goal of SOAR is to characterize the clinical and economic impact of clinicians' responses to major bleeding complications and pre-procedural concerns for bleeding risk in patients treated with oral anticoagulants (warfarin…
- Trial name
- SOAR (NCT02745054)
- Testing
- mgt of bleeding concerns/complications of oral anticoagulants
- Where
- 9 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Hospital Quality Foundation
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Embolism and Thrombosis, Hemorrhage
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
The purpose of this study is to investigate the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs).
- Trial name
- ADR-OAC (NCT02720328)
- Testing
- Blood samples for DOAC measurement
- Where
- 2 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Atrial Fibrillation
Assessment of Atrial Fibrillation in Emergency Department
Atrial Fibrillation (AF) is the most common disorder of the rhythm disturbance, especially in older adults. The incidence and prevalence of AF increases significantly with age: less than one new case per 1000/year before age 40…
- Trial name
- ACFA (NCT03836339)
- Where
- France
- Volunteers
- 1,369 people
- Sponsor
- RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône
Transcatheter Aortic Valve Replacement
Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)
The main objective of this study is to demonstrate that a single anticoagulant therapy is superior to a combination of anticoagulant and antiplatelet therapy on the net clinical benefit estimated at 12 months after a…
- Trial name
- AVATAR (NCT02735902)
- Testing
- Vitamin K antagonist or direct oral anticoagulant treatment, Aspirin
- Where
- 6 sites in France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Healthy
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
The primary purpose of this study is to evaluate the reversal of the anticoagulant effects of milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa) in healthy participants as…
- Trial name
- NCT04543383
- Testing
- Milvexian, 4-Factor Prothrombin Complex Concentrate (4F-PCC), Recombinant Human Factor VIIa (rFVIIa)
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to…
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Trial name
- eVTE (NCT06232551)
- Testing
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Where
- United States
- Volunteers
- 152,000 people
- Sponsor
- Scott C. Woller, MD
Atrial Fibrillation
Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation
This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding…
- Trial name
- NCT02504177
- Testing
- novel oral anticoagulant for 30 days, novel oral anticoagulant for 24 hour
- Where
- South Korea
- Volunteers
- 433 people
- Sponsor
- Yonsei University
Atrial Fibrillation (AF), Coronary Artery Disease
OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation
The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter…
- Conditions
- Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent
- Trial name
- OPTIA-AF (NCT07496281)
- Testing
- Oral anticoagulation, Single antiplatelet therapy
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Ewha Womans University Mokdong Hospital
GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Anticoagulation After GI Bleeding Pilot Study and Registry
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related…
- Trial name
- PANTHER-GI (NCT05290857)
- Testing
- Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Clot Formation and Platelet Aggregation in Point of Care Testing
Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study
The purpose of this study is determine whether point of care coagulation testing is able to map the anticoagulatory effects of new oral anticoagulants dabigatran and rivaroxaban.
- Trial name
- NCT01704053
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Prevention, Venous Thromboembolism
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Trial name
- NCT01181167
- Testing
- edoxaban, enoxaparin sodium
- Where
- 2 sites in Japan
- Volunteers
- 610 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Non-Valvular Atrial Fibrillation (NVAF)
A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
The purpose of this study is to provide real-world data useful to address the factors associated to the administration of oral anticoagulants in the elderly population affected by non-valvular atrial fibrillation (NVAF), in…
- Trial name
- PRESBUS (NCT05232643)
- Where
- Italy
- Volunteers
- 636 people
- Sponsor
- Bristol-Myers Squibb
Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction
Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)
Benign prostatic hyperplasia (BPH) is a very common pathology of the aging man with an incidence that rises from 40% in men aged 50 to 60 years to 90% in men over 80 years.
- Trial name
- SOAP (NCT03297281)
- Testing
- Maintenance of OAC in surgery of BPH by PVP., Discontinuation of OAC in surgery of BPH by PVP.
- Where
- France
- Volunteers
- 389 people
- Sponsor
- Clinique Pasteur
Pulmonary Embolism
Deferment of Imaging for Pulmonary Embolism
Background. Management of patients with suspected Pulmonary Embolism (PE) is problematic if diagnostic imaging is not available.
- Trial name
- NCT00381511
- Testing
- low molecular weight heparin
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Atrial Fibrillation
COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2
Atrial fibrillation (AF) is a leading cause of cardiovascular mortality and morbidity. Asian patients with AF have a higher rate of major bleeding including intracranial hemorrhage (ICH) compared to non-Asians.
- Trial name
- NCT06396299
- Testing
- No intervention
- Where
- 33 sites in Thailand
- Volunteers
- 4,000 people
- Sponsor
- Mahidol University
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture
Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage.
- Conditions
- ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF), Mitral Valve Surgery, Stroke (in Patients With Atrial Fibrillation)
- Trial name
- ATRI-LASH (NCT07360899)
- Testing
- LAA closure using the AtriLASH
- Where
- Serbia
- Volunteers
- 200 people
- Sponsor
- Institute of Cardiovascular Diseases, Vojvodina